Table 1.

Association between the clinical characteristics and MEG3 expression level with the overall survival and disease-free survival of CRC patients (N = 371).

	Overall survival				Disease-free survival
Variable	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)	P-value	HR (95% CI)	P value	HR (95% CI)	P-value	HR (95% CI)	P value
TNM stage (III vs. I+ II)	2.34 (1.26–4.32)	0.007	2.48 (1.33–4.60)	0.004	2.26 (1.38–3.69)	0.001	2.32 (1.42–3.80)	<0.001
Depth of invasion [(T3 + T4) vs. (T1 + T2)]	1.21 (0.60–2.44)	0.591			1.57 (0.92–2.69)	0.099
Sex (women vs. men)	1.08 (0.61–1.92)	0.785			0.92 (0.57–1.47)	0.718
Tumor location (rectum vs.colon)	0.82 (0.42–1.59)	0.554			1.25 (0.76–2.06)	0.379
Age (>60 vs. ≤60 years)	1.32 (0.74–2.35)	0.352			1.01 (0.63–1.62)	0.967
Differentiation
Moderately vs. well	1.74 (0.42–7.25)	0.444			1.25 (0.45–3.48)	0.659
Poorly vs. well	1.65 (0.27–9.91)	0.585			1.28 (0.34–4.78)	0.713
Treatment (yes vs. no)	1.85 (0.73–4.68)	0.195			2.13 (0.97–4.67)	0.058
CEA (>20 ng/mL vs. <20 ng/mL)	2.91 (1.48–5.72)	0.002	2.83 (1.28–6.25)	0.010	2.08 (1.12–3.88)	0.021	2.11 (1.03–4.32)	0.041
CA199 (>22.32 U/mL vs. <22.32 U/mL)	1.79 (1.01–3.18)	0.047	1.41 (0.75–2.67)	0.289	1.30 (0.80–2.12)	0.284
MEG3 (high vs. low)	0.37 (0.19–0.74)	0.005	0.34 (0.16–0.71)	0.004	0.45 (0.27–0.78)	0.004	0.43 (0.25–0.76)	0.004